Unichem Laboratories Share Price Extends Rally as Polunin Emerging Markets Small Cap Fund Picks Up 0.85% Stake for Rs 38.84 Crore

Unichem Laboratories share price Rs 664.50, up 2.14% (10 Jul, 9:15 AM). Polunin fund bought 6 lakh shares, 0.85% stake, Rs 38.84 crore at Rs 646.44. 52W high Rs 685.95. Mcap Rs 4,586 crore.

The Unichem Laboratories share price extended its winning run on 10 July 2026, trading 2.14% higher at Rs 664.50, after bulk deal data revealed a marquee institutional purchase. Polunin Emerging Markets Small Cap Fund, managed by London-based Polunin Capital Partners, acquired 6 lakh shares representing a 0.85 percent stake in the pharmaceutical company for Rs 38.84 crore.

The purchase price worked out to Rs 646.44 per share. The disclosure follows a blistering previous session in which the stock closed 13.93 percent or Rs 79.65 higher at Rs 651.30, its sharpest single-day gain in around 15 months.

Click Here – Get Free Investment Predictions

Unichem Laboratories Share Price and Deal Snapshot

Cross-Check Smallcap Ideas with a SEBI-Registered Investment Advisor

Why the Polunin Purchase Matters

Foreign institutional interest in a smallcap pharma name is a meaningful sentiment signal. Dedicated emerging markets small cap funds like Polunin’s typically run concentrated, research-heavy portfolios, so a fresh 0.85 percent position suggests conviction in the company’s earnings trajectory rather than a passive allocation.

The timing is equally notable. The fund bought into strength, paying Rs 646.44 per share just below the stock’s freshly minted 52-week high of Rs 685.95 touched on 9 July 2026. Institutions buying after a 13.93 percent single-day surge indicates they expect the re-rating to continue rather than fade.

Unichem Laboratories Share Price: From 52-Week Low to Multibagger Move

The journey of the Unichem Laboratories share price over the past year has been dramatic. From a 52-week low of Rs 280.00 recorded on 30 March 2026, the Unichem Laboratories share price has risen roughly 132 percent to current levels. Even after that run, it trades about 5 percent below its 52-week high, keeping the breakout structure intact on the charts.

The company’s market capitalisation now stands at around Rs 4,586 crore. Sustained institutional accumulation at these levels would deepen the shareholder base and could reduce the volatility that typically accompanies smallcap pharma stocks.

What Should Investors Watch Next

Investors tracking the Unichem Laboratories share price should watch for further bulk or block deal disclosures, shareholding pattern changes in the September quarter, quarterly earnings delivery, and USFDA or regulatory updates on its manufacturing facilities. After a 13.93 percent single-day jump, some consolidation or profit booking would be normal and healthy.

About Unichem Laboratories

Unichem Laboratories is one of India’s older pharmaceutical companies, with a history spanning more than eight decades. After selling its domestic formulations business to Torrent Pharmaceuticals in 2017, the company reinvented itself as an export-focused player, supplying formulations and active pharmaceutical ingredients primarily to the United States and other regulated markets from its manufacturing sites in Goa, Ghaziabad, Baddi, Roha and Pithampur.

The strategic pivot took time to bear fruit, and the stock spent years in consolidation while the US generics market battled price erosion. The recent turnaround in profitability, aided by a better pricing environment in US generics and improved capacity utilisation, is what has reignited institutional interest in the counter.

What Is Driving the Re-Rating in Unichem Laboratories Share Price

Three forces are converging. First, earnings momentum: the company has been reporting improving margins as operating leverage kicks in across its API and formulations plants. Second, sector tailwinds: US generic drug pricing has stabilised after years of deflation, benefiting export-focused Indian manufacturers. Third, flows: the rise in the Unichem Laboratories share price into a new 52-week high zone has attracted momentum capital, now validated by a dedicated emerging markets fund taking a disclosed position.

The 13.93 percent surge in the previous session, the sharpest in about 15 months, came on heavy volumes, and the follow-through buying on 10 July suggests supply remains limited at current levels. Bulk deal counterparties on the sell side will be visible in exchange data, and continuity of institutional accumulation is the metric to watch.

Risks After a Sharp Rally

A 132 percent rise from the 52-week low compresses the margin of safety. Key risks include USFDA inspection outcomes at manufacturing facilities, renewed price erosion in US generics, currency swings, and the natural volatility of a smallcap where a single fund’s exit can move the price. Investors should size positions accordingly rather than extrapolating the recent trajectory.

Unichem Laboratories Share Price History: A Stock Rediscovered

The Unichem Laboratories share price spent much of the past several years overlooked by institutions, trading at a fraction of its cash-adjusted value while the export transition played out. The move from Rs 280 in late March 2026 to nearly Rs 686 by early July compresses years of patient repair into a single quarter of price action, a pattern that often emerges when earnings inflect in an under-owned smallcap.

For perspective, the Unichem Laboratories share price has now delivered one of the strongest three-month runs in the pharma smallcap basket, and the Polunin purchase at Rs 646.44 confirms that at least one dedicated global fund believes the earnings recovery justifies these levels. The next quarterly result becomes the natural checkpoint: continued margin expansion would ratify the re-rating, while any stumble would test the durability of the new shareholder base that has assembled between Rs 550 and Rs 686.

Download the Univest iOS App or Univest Android App to track Unichem Laboratories live prices and bulk deal alerts.

Conclusion

The Polunin Emerging Markets Small Cap Fund’s Rs 38.84 crore purchase adds institutional weight behind the rally in the Unichem Laboratories share price. With the Unichem Laboratories share price up about 132 percent from the 52-week low and hovering near record territory, the deal validates the momentum, though fresh investors should be mindful of the sharpness of the recent move before chasing the price.

FAQs on Unichem Laboratories Share Price and the Polunin Deal

Why is the Unichem Laboratories share price in focus today?

Ans. The Unichem Laboratories share price is in focus because Polunin Emerging Markets Small Cap Fund, managed by Polunin Capital Partners, acquired 6 lakh shares representing a 0.85% stake in the company for Rs 38.84 crore through a bulk deal at Rs 646.44 per share.

Who is Polunin Capital Partners?

Ans. Polunin Capital Partners is a London-based emerging markets investment manager. Its Polunin Emerging Markets Small Cap Fund invests in smaller companies across emerging markets, and its entry into Unichem Laboratories signals institutional confidence in the Indian pharma company.

At what price did Polunin buy the Unichem Laboratories stake?

Ans. The fund purchased 6 lakh shares of Unichem Laboratories at an average price of Rs 646.44 per share, taking the total deal value to Rs 38.84 crore and its purchased stake to 0.85 percent of the company.

How has the Unichem Laboratories share price performed recently?

Ans. The stock has been in strong momentum. In the previous trading session it closed 13.93 percent or Rs 79.65 higher at Rs 651.30, its best single-day gain in about 15 months, and it is trading around Rs 664.50 on 10 July 2026, up another 2.14 percent.

What is the 52-week high and low of Unichem Laboratories?

Ans. Unichem Laboratories touched a 52-week high of Rs 685.95 on 9 July 2026 and a 52-week low of Rs 280.00 on 30 March 2026. At current levels the stock trades about 5 percent below its 52-week high and roughly 132 percent above its 52-week low.

What is the market capitalisation of Unichem Laboratories?

Ans. The market capitalisation of Unichem Laboratories stands at approximately Rs 4,586 crore as of 10 July 2026, placing it in the smallcap pharmaceutical segment of the Indian market.

Should investors buy Unichem Laboratories after the Polunin deal?

Ans. Institutional buying is a positive signal but not a guarantee of returns, especially after a sharp rally. Investors should assess fundamentals, valuations and their own risk profile, and consult a SEBI-registered investment advisor before acting. This article is educational and not investment advice.